cyclopentane has been researched along with Androgen-Independent Prostatic Cancer in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, J; Ho, SM; Jia, L; Lam, HM; Medvedovic, M; Ouyang, B; Vessella, RL; Wang, J; Wu, CL; Ying, J | 1 |
| Feng, Y; Fu, S; Guo, X; Jeong, LS; Jia, L; Li, L; Liang, Y; Wang, X; Yan, Z; Yu, J; Yu, X; Zhang, W; Zhang, Y; Zhao, H | 1 |
2 other study(ies) available for cyclopentane and Androgen-Independent Prostatic Cancer
| Article | Year |
|---|---|
Targeting GPR30 with G-1: a new therapeutic target for castration-resistant prostate cancer.
Topics: Androgens; Animals; Biomarkers, Tumor; Blotting, Western; Cell Proliferation; Chromatin Immunoprecipitation; Cohort Studies; Cyclopentanes; Follow-Up Studies; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immunoenzyme Techniques; Male; Mice; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Prostatic Neoplasms, Castration-Resistant; Quinolines; Real-Time Polymerase Chain Reaction; Receptors, Androgen; Receptors, Estrogen; Receptors, G-Protein-Coupled; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
Radiosensitization by the investigational NEDD8-activating enzyme inhibitor MLN4924 (pevonedistat) in hormone-resistant prostate cancer cells.
Topics: Cell Line, Tumor; Cyclopentanes; Enzyme Inhibitors; Humans; Male; NEDD8 Protein; Prostatic Neoplasms, Castration-Resistant; Pyrimidines; Radiation-Sensitizing Agents | 2016 |